Long-Acting Bronchodilation with Once-Daily Dosing of Tiotropium (Spiriva) in Stable Chronic Obstructive Pulmonary Disease

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/ajrccm.161.4.9903044 ◽

2000 ◽

Vol 161 (4) ◽

pp. 1136-1142 ◽

Author(s):

MICHAEL R. LITTNER ◽

JONATHAN S. ILOWITE ◽

DONALD P. TASHKIN ◽

MITCHELL FRIEDMAN ◽

CHARLES W. SERBY ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Download Full-text

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

Respiratory Medicine ◽

10.1016/j.rmed.2019.05.010 ◽

2019 ◽

Vol 153 ◽

pp. 38-43 ◽

Author(s):

James F. Donohue ◽

Edward Kerwin ◽

Sanjay Sethi ◽

Brett Haumann ◽

Srikanth Pendyala ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Phase 3 ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Download Full-text

Once daily Long-acting beta2 -agonists/Inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd012355 ◽

2016 ◽

Author(s):

Agnieszka Sliwka ◽

Milosz Jankowski ◽

Iwona Gross-Sondej ◽

Roman Nowobilski ◽

Malgorzata M Bala

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Inhaled Corticosteroids ◽

Chronic Obstructive ◽

Muscarinic Antagonists ◽

Obstructive Pulmonary Disease ◽

Download Full-text

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s35990 ◽

2012 ◽

pp. 673 ◽

Author(s):

Charlotte Ulrik

Keyword(s):

Systematic Review ◽

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Clinical Benefit ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Glycopyrronium Bromide ◽

Download Full-text

A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease

Respiratory Medicine ◽

10.1016/j.rmed.2015.02.012 ◽

2015 ◽

Vol 109 (5) ◽

pp. 596-605 ◽

Author(s):

M. Reza Maleki-Yazdi ◽

Ekkehard Beck ◽

Alan L. Hamilton ◽

Lawrence Korducki ◽

Paul Koker ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Phase Ii ◽

Daily Treatment ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Dose Ranging ◽

Long Acting ◽

Download Full-text

LAS 100977,* a novel once-daily long-acting ??-agonist, has shown potential for the treatment of asthma and chronic obstructive pulmonary disease

Inpharma Weekly ◽

10.2165/00128413-200816360-00009 ◽

2008 ◽

Vol &NA; (1636) ◽

pp. 7

Author(s):

&NA;

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Long Acting ◽

Download Full-text

New once-daily, long-acting inhaled β2-agonist: what role will it play in the treatment of chronic obstructive pulmonary disease?

Polish Archives of Internal Medicine ◽

10.20452/pamw.973 ◽

2010 ◽

Vol 120 (10) ◽

pp. 381-382

Author(s):

R. Andrew McIvor

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Long Acting ◽

Download Full-text

Once daily long‐acting beta 2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease

International Journal of Nursing Practice ◽

10.1111/ijn.12982 ◽

2021 ◽

Author(s):

Abdullahi S. Ibrahim

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Muscarinic Antagonists ◽

Obstructive Pulmonary Disease ◽

Beta 2 ◽

Download Full-text

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s59673 ◽

2014 ◽

pp. 813 ◽

Author(s):

Neil Roskell ◽

Antonio Anzueto ◽

Alan Hamilton ◽

Bernd Disse ◽

Karin Becker

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Indirect Comparison ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Beta Agonists ◽

Download Full-text

Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd012930 ◽

2018 ◽

Author(s):

Usman Maqsood ◽

David JW Evans ◽

Terence N Ho ◽

Karen Palmer ◽

Fiona JR Eccles ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Muscarinic Antagonists ◽

Obstructive Pulmonary Disease ◽

Download Full-text

Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials

Pulmonary Pharmacology & Therapeutics ◽

10.1016/j.pupt.2019.101808 ◽

2019 ◽

Vol 57 ◽

pp. 101808 ◽

Author(s):

James F. Donohue ◽

Gregory Feldman ◽

Sanjay Sethi ◽

Chris N. Barnes ◽

Srikanth Pendyala ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Clinical Trials ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Cardiovascular Safety ◽

Phase 3 ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Download Full-text